Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

NCI Addresses Tobacco- Related Cancers in Women

March 1, 2005
By Roy S. Herbst, MD, PhD
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 3
Volume 14
Issue 3

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.

BETHESDA, Maryland-Aworking group of the National CancerInstitute (NCI) has released a seriesof recommendations aimed atstimulating scientific research intotobacco-related cancers in women andtranslating discoveries into evidencebasedinterventions to prevent thecancers worldwide.The report, "Women, Tobacco,and Cancer: An Agenda for the 21stCentury," noted that the incidenceand mortality rates of smoking-relatedcancers in US women soared duringthe second half of the 20th century.Lung cancer mortality in womenincreased 600% between 1950 and1997, making it the leading cause ofcancer death in females.The NCI working group comprisedexperts from the institute, other federalagencies, nongovernment researchinstitutions, and advocacygroups. Members drew in part on informationcontained in several recentreports, including the 2001 SurgeonGeneral's report, "Women and Smoking,"which highlighted the importanceof gender-specific research intotobacco use and effects.The panel set several key goals forfuture research into tobacco-relatedcancers in women:

  • Increase our understanding ofsex differences across the broad rangeof research on women, tobacco, andcancer.
  • Develop new and more effectiveinterventions to prevent and treat tobaccouse and environmental tobaccosmoke exposure among womenand girls, especially in populations atgreatest risk; expand partnerships,networks, and innovative researchplatforms to ensure the widespreaddelivery of these interventions.
  • Improve national and globalevaluation and surveillance of thehealth hazards related to tobacco useand ETS exposure, specifically, ofwomen's and girls' knowledge, attitudes,and behaviors related to tobaccouse and associated risks.The working group emphasizedthat there is a critical need to betterunderstand sex differences as they relateto all phases of tobacco addictionand tobacco-related diseases."This includes genetic, molecular,cellular, neurobiological, biobehavioral,and hormonal factors thatplay a critical role in tobacco addictionand in the etiology of cancersand other diseases caused by tobacco,"the working group stated.Researchers also need to decipherthe etiologic role of gene-hormoneenvironmentinteractions in the cancers,and discover new methods forprevention and treatment of tobaccoaddiction. In addition, the NCI panelsaid that development of better treatmentand prevention techniques requiresidentifying the behavioral,psychosocial, sociocultural, and environmentalfactors that influence tobaccouse, exposure to second-handsmoke, and disease risk.

Translating basic and applied researchinto effective interventions willdepend on advances in four areas:

  • Using evidence from animalstudies, pilot projects, and small clinicaland community studies to developnew interventions for prevention,cessation, and treatment.
  • Finding ways to use or modifyexisting infrastructures to rapidly evaluatethe efficacy of promising treatmentsand the effectiveness and costefficiencyof proven small-scaleprograms and policies.
  • Exploring and strengthening thepositive health effects of tobacco-control policies on women and girls.
  • Monitoring the harmful effectsof tobacco marketing on females.

Delivering the proven results of researchand development efforts willdepend on finding ways to increasethe appeal, access, affordability, anduse of effective interventions, theworking group said. This, in turn, willrequire identifying and targeting messagesand strategies that successfullyinvolve individuals and organizationsin evidence-based tobacco-controlpolicies. Data from research-includingsurveillance, policy, economic,and cultural studies-need to be moreavailable to health care workers, policymakers, and the public, the paneladded.The NCI report also stressed theimportance of partnerships betweengovernment agencies, nongovernmentorganizations, private foundations,corporations, academic institutions,and community groups in acceleratingprogress in tobacco-related interventionsaimed at women and girls.Finally, the panel cited the importanceof local, national, and worldwideevaluation and surveillance indetermining the progress of efforts toreduce tobacco use, ETS exposure,and tobacco-related cancers amongwomen and girls, and to make changesin programs when needed.

Articles in this issue

Smoking Speeds Progression of Pancreas Ca
Alcohol, Obesity, and Smoking Risk Factors for HCC
Eloxatin Receives FDA Indication for Use in Adjuvant Treatment of Stage III Colon Cancer
Adding Bevacizumab Improves Response to Oxaliplatin Regimens
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Avastin Enhances FOLFOX Efficacy
Panitumumab, Anti-EGFR MoAb,Promising in Colon Cancer
Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer
Study Strengthens Evidence of Link Between Liver Cancer and Diabetes
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Capecitabine Equal to Bolus 5-FU/LV in Adjuvant Therapy for Colon Cancer
Three Adjuvant 5-FU/RT Regimens Are Equally Effective
Single-Agent Cetuximab Active in Patients With Refractory Colon Cancer
XELIRI Shows Promise as First-Line Treatment for Advanced Colorectal Ca
UFT Provides ‘Equivalent’ Survival and Quality of Life to 5-FU in Stage II/III Colorectal Cancer
Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content
Advertisement

3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.

Low-Dose CT Screening for Lung Cancer Shows Large-Scale Efficacy

Russ Conroy
April 29th 2025
Article

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.

Lung Cancer Screening Adherence Decreases Across Subsequent Testing

Russ Conroy
April 24th 2025
Article

Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.


A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

Russ Conroy
April 23rd 2025
Article

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Related Content
Advertisement

3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.

Low-Dose CT Screening for Lung Cancer Shows Large-Scale Efficacy

Russ Conroy
April 29th 2025
Article

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.

Lung Cancer Screening Adherence Decreases Across Subsequent Testing

Russ Conroy
April 24th 2025
Article

Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.


A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

Russ Conroy
April 23rd 2025
Article

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.